Skip to main content

Table 2 Patient characteristics used as outcome measures after application of adjustment or matching procedures using the variables given in Table 1

From: Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET

 

Triple always

Triple not always

All

Number

162

96

258

FVC (%predicted)

69.1 (± 16.9)

75.9 (± 16.4)**

71.6 (± 17.0)

ITGV (%predicted)

166 (± 37.5)

156 (± 35.8)*

162 (± 37.1)

PaCO2 (mmHg)

39.3 (± 4.79)

38.5 (± 4.37)

39.0 (± 4.65)

PaO2 (mmHg)

65.2 (± 7.98)

66.5 (± 8.46)

65.7 (± 8.17)

SaO2 (%)

93.5 (± 2.44)

93.8 (± 2.68)

93.6 (± 2.53)

IPAQ (score)

4020 (± 3960)

4300 (± 4020)

4120 (± 3970)

EQ-VAS (score)

49.7 (± 15.5)

52.5 (± 15.7)

50.7 (± 15.6)

SGRQ activity (score)

74.7 (± 20.3)

65.4 (± 22.2)***

71.3 (± 21.5)

SGRQ impact (score)

41.3 (± 19.1)

39.3 (± 17.4)

40.5 (± 18.5)

SGRQ symptoms (score)

66.9 (± 16.4)

65.6 (± 14.0)

66.4 (± 15.6)

6-MWD (m)

358 (± 98.4)

399 (± 115)**

374 (± 107)

PHQ-9 (score)

7.42 (± 4.58)

8.14 (± 4.56)

7.69 (± 4.58)

CAT1 cough (score)

2.56 (± 0.956)

2.70 (± 0.922)

2.61 (± 0.944)

CAT2 phlegm (score)

2.76 (± 1.06)

2.71 (± 1.05)

2.74 (± 1.06)

CAT3 chest tightness (score)

2.31 (± 1.25)

2.32 (± 1.11)

2.31 (± 1.20)

CAT4 breathlessness (score)

4.18 (± 0.780)

4.10 (± 0.908)

4.15 (± 0.829)

CAT5 activity (score)

3.12 (± 1.20)

2.82 (± 1.23)

3.01 (± 1.22)

CAT6 confidence (score)

1.66 (± 1.25)

1.41 (± 1.28)

1.57 (± 1.27)

CAT7 sleep (score)

2.98 (± 1.35)

2.65 (± 1.31)

2.55 (± 1.33)

CAT8 energy (score)

2.98 (± 0.958)

3.07 (± 0.983)

3.01 (± 0.967)

CAT Sum (score)

22.1 (± 6.25)

21.8 (± 6.03)

22.0 (± 6.16)

  1. Mean values and standard deviations are given. The groups “Triple always” and “Triple not always” were compared with each other using the t-test or wilcoxon rank-sum test, depending on the distribution of the data. Significance levels are indicated as *p < 0.05, **p < 0.01, ***p < 0.001